- Home
- TCI vs KYTX Comparison
TCI vs KYTX Comparison
Compare TCI & KYTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TCI
- KYTX
- Stock Information
- Founded
- TCI 1983
- KYTX 2018
- Country
- TCI United States
- KYTX United States
- Employees
- TCI N/A
- KYTX N/A
- Industry
- TCI Real Estate
- KYTX
- Sector
- TCI Finance
- KYTX
- Exchange
- TCI Nasdaq
- KYTX NYSE
- Market Cap
- TCI 240.5M
- KYTX 196.4M
- IPO Year
- TCI N/A
- KYTX 2024
- Fundamental
- Price
- TCI $29.51
- KYTX $3.79
- Analyst Decision
- TCI
- KYTX Buy
- Analyst Count
- TCI 0
- KYTX 5
- Target Price
- TCI N/A
- KYTX $23.20
- AVG Volume (30 Days)
- TCI 4.5K
- KYTX 383.0K
- Earning Date
- TCI 11-07-2024
- KYTX 02-12-2025
- Dividend Yield
- TCI N/A
- KYTX N/A
- EPS Growth
- TCI N/A
- KYTX N/A
- EPS
- TCI 0.37
- KYTX N/A
- Revenue
- TCI $49,821,000.00
- KYTX N/A
- Revenue This Year
- TCI N/A
- KYTX N/A
- Revenue Next Year
- TCI N/A
- KYTX N/A
- P/E Ratio
- TCI $80.90
- KYTX N/A
- Revenue Growth
- TCI 4.46
- KYTX N/A
- 52 Week Low
- TCI $26.29
- KYTX $3.77
- 52 Week High
- TCI $43.40
- KYTX $30.60
- Technical
- Relative Strength Index (RSI)
- TCI 58.03
- KYTX 36.30
- Support Level
- TCI $27.82
- KYTX $4.50
- Resistance Level
- TCI $30.95
- KYTX $4.60
- Average True Range (ATR)
- TCI 0.94
- KYTX 0.55
- MACD
- TCI 0.04
- KYTX -0.10
- Stochastic Oscillator
- TCI 57.43
- KYTX 0.58
About TCI Transcontinental Realty Investors Inc.
Transcontinental Realty Investors Inc is a fully integrated externally managed real estate company. It operates multifamily and commercial properties throughout the southern United States and also invests in mortgage notes receivable and in the land that is either held for appreciation or development. The company has two business segments: the acquisition, development, ownership, and management of multifamily properties which include the rental of apartments (Residential Segment) and other tenant services, including parking and storage space rental, and the acquisition, development, ownership, and management of commercial properties which are office properties(Commercial Segment). It includes the rental of office space and other tenant services, including parking and storage space rental.
About KYTX KYVERNA THERAPEUTICS INC
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.